0
Obstructive Lung Diseases |

Oscillatory Positive Expiratory Pressure (oPEP) Treatment in Chronic Obstructive Pulmonary Disease

Sarah Svenningsen, BS; Miranda Kirby, BS; Jason Suggett, PhD; Nikhil Kanhere, BS; Aasim Hasany, MD; David McCormack, MD; Grace Parraga, PhD
Author and Funding Information

Robarts Research Institute, London, ON, Canada


Chest. 2013;144(4_MeetingAbstracts):741A. doi:10.1378/chest.1698587
Text Size: A A A
Published online

Abstract

SESSION TITLE: Dyspnea in COPD

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Sunday, October 27, 2013 at 04:15 PM - 05:15 PM

PURPOSE: We evaluated a handheld oscillating positive expiratory pressure (oPEP) device (Aerobika®, Trudell Medical International, Canada) that combines positive expiratory pressure therapy and airway vibrations with the goal being mobilization of pulmonary secretions and consequent improved dyspnea. The purpose of this pilot study was to evaluate the safety and efficacy of the oPEP device in subjects with chronic obstructive pulmonary disease (COPD). Efficacy was evaluated using pulmonary function test results, validated questionnaires as well as pulmonary functional imaging using hyperpolarized 3He magnetic resonance imaging (MRI) and safety was evaluated using adverse events (AE).

METHODS: Seventeen subjects with COPD were enrolled in an eight-week cross-over study with subjects randomized to receive the device (or no device) for four weeks daily use and then crossed over. All subjects underwent pulmonary function tests, 6-minute walk test and answered the St. George’s Respiratory and Patient Evaluation Questionnaires at baseline, and after 2 and 4 weeks during each cross-over period. Hyperpolarized 3He MRI was performed at baseline and at the end of each 4 week treatment period for the measurement of ventilation defect percent (VDP).

RESULTS: Fourteen COPD subjects (6 males; mean age=73±5 yrs) completed the study. Three subjects withdrew; two subjects because of AE judged unrelated to the use of oPEP and one subject withdrew without a reason. There were nine mild-moderate AE in seven subjects, all of which judged unrelated to oPEP. For all subjects, dyspnea was significantly reduced after oPEP therapy (p=0.03). For six subjects with improved VDP, the ease in bringing up sputum was significantly increased after oPEP therapy (p=0.02).

CONCLUSIONS: Four-weeks of oPEP use was well-tolerated in COPD subjects. In COPD subjects not phenotyped with respect to emphysema or airways disease/bronchiectasis, oPEP therapy showed improved/reduced dyspnea and in a subset of subjects with objective imaging improvements there was also increased ease in bringing up sputum.

CLINICAL IMPLICATIONS: In COPD subjects, the use of oPEP can be considered safe and related to improvements in dyspnea.

DISCLOSURE: Grace Parraga: Grant monies (from industry related sources): Recieved grant in aid from Trudell Medical International The following authors have nothing to disclose: Sarah Svenningsen, Miranda Kirby, Jason Suggett, Nikhil Kanhere, Aasim Hasany, David McCormack

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543